Power of Technology to Transform Delirium Severity Measurement in the ICU

Overview

About this study

The purpose of this study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools (CAM-ICU-7, ICDSC).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Aim 1-3 Patient Participants

Age ≥ 50 years old;
Estimated length of stay ≥ 24 hours in ICU; and
Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.

Aim 3 Nurse Clinician Participants

Age ≥ 18 years old;
Employed by Mayo Clinic;
Assigned to care for study patient for > 4 hours.

Aim 3 Care Partner Participants

Age ≥ 18 years old;
Proxy decision maker for patient participant;
Willing to complete survey (verbal consent).

Exclusion Criteria:

Aim 1-3 Patient Participants

Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal;
Admitted for acute neuronal injury;
Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf); or
Language (does not speak English).

Aim 3 Nurse Clinician Participants

Not assigned to study patient.

Aim 3 Care Partner Participants

Did not visit patient in ICU during study period;
Already listed above in previous protocol version, was not copied/mentioned here.

Eligibility last updated 12/1/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Heidi Lindroth, Ph.D., R.N.	Open for enrollment	Contact information: Division of Nursing Research Study Team (507) 422-5523 rstnursingresearch@mayo.edu
Jacksonville, Fla. Mayo Clinic principal investigator Anirban Bhattacharyya, M.D., M.S.	Open for enrollment	Contact information: Kathleen Leistikow (507) 422-3994 Leistikow.Kathleen@mayo.edu
Eau Claire, Wis. Mayo Clinic principal investigator Heidi Lindroth, Ph.D., R.N.	Open for enrollment	Contact information: Heidi Lindroth Ph.D., R.N. (507) 284-3662 Lindroth.Heidi@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Arun Jayaraman, M.D., Ph.D.	Open for enrollment	Contact information: Kathleen Leistikow (507) 422-3994 Leistikow.Kathleen@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Heidi Lindroth, Ph.D., R.N.

Open for enrollment

Contact information:

Division of Nursing Research Study Team

(507) 422-5523

rstnursingresearch@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Anirban Bhattacharyya, M.D., M.S.

Open for enrollment

Contact information:

Kathleen Leistikow

(507) 422-3994

Leistikow.Kathleen@mayo.edu

Eau Claire, Wis.

Mayo Clinic principal investigator

Heidi Lindroth, Ph.D., R.N.

Open for enrollment

Contact information:

Heidi Lindroth Ph.D., R.N.

(507) 284-3662

Lindroth.Heidi@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Arun Jayaraman, M.D., Ph.D.

Open for enrollment

Contact information:

Kathleen Leistikow

(507) 422-3994

Leistikow.Kathleen@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials